Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Phase 1/2 Terminated
53 enrolled 22 charts
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Phase 1/2 Terminated
3 enrolled 9 charts
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Phase 1/2 Terminated
8 enrolled 8 charts
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Phase 1/2 Terminated
1 enrolled 5 charts
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Phase 1/2 Terminated
6 enrolled 13 charts
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
Phase 1/2 Terminated
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Phase 1/2 Terminated
12 enrolled 16 charts
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Phase 1/2 Terminated
9 enrolled 14 charts
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Phase 1/2 Terminated
3 enrolled 13 charts
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Phase 1/2 Terminated
14 enrolled 17 charts
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Phase 1/2 Terminated
3 enrolled 10 charts
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1/2 Terminated
21 enrolled 11 charts
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
Phase 1/2 Terminated
6 enrolled 13 charts
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
Phase 1/2 Terminated
31 enrolled 18 charts
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Phase 1/2 Terminated
14 enrolled 8 charts
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Phase 1/2 Terminated
15 enrolled 5 charts
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Phase 1/2 Terminated
7 enrolled 10 charts
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase 1/2 Terminated
24 enrolled 18 charts
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
Phase 1/2 Terminated
42 enrolled 16 charts
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase 1/2 Terminated
15 enrolled 14 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
31 enrolled 8 charts
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
Phase 1/2 Terminated
10 enrolled 7 charts
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Phase 1/2 Terminated
22 enrolled 21 charts
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
81 enrolled 16 charts
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase 1/2 Terminated
5 enrolled 9 charts
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
Phase 1/2 Terminated
8 enrolled 20 charts
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Phase 1/2 Terminated
26 enrolled 33 charts
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
2 enrolled 4 charts
Dinaciclib in Treating Patients With Stage III-IV Melanoma
Phase 1/2 Terminated
12 enrolled 9 charts
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Terminated
46 enrolled 12 charts
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
Phase 1/2 Terminated
5 enrolled 7 charts
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
Phase 1/2 Terminated
40 enrolled 11 charts
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2 Terminated
13 enrolled 13 charts
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase 1/2 Terminated
34 enrolled 20 charts
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
Phase 1/2 Terminated
1 enrolled 8 charts
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 1/2 Terminated
9 enrolled 13 charts
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Phase 1/2 Terminated
3 enrolled 8 charts
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
32 enrolled 7 charts
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase 1/2 Terminated
85 enrolled 17 charts
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Terminated
5 enrolled 7 charts
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
Phase 1/2 Terminated
64 enrolled
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
Phase 1/2 Terminated
46 enrolled
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Phase 1/2 Terminated
46 enrolled
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Phase 1/2 Terminated
1 enrolled 8 charts
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
Phase 1/2 Terminated
37 enrolled 9 charts